Skip to main content
. Author manuscript; available in PMC: 2009 Jan 22.
Published in final edited form as: Ann Neurol. 2006 Jun;59(6):952–962. doi: 10.1002/ana.20873

Table 1.

Demographics of Frontotemporal Dementia Patients

Demographics Total Tauopathy FTLD-Ua DLDH AD Other
Age at onset (range), yr 60.4 (30-82),
n = 111b
61.0 (30-77),
n = 51
60.3 (46-79),
n = 33
54.8 (43-80),
n = 4
60.3 (34-82),
n = 19
59.8 (50-70),
n = 4
Sex, M:F (% male) 58:56 (50.9%) 28:25 (53%) 14:19 (42%) 2:2 (50%) 10:9 (53%) 4:1 (80%)
Education (range), yr 15.3 (8-23),
n = 85
15.3 (10-21),
n = 36
15.2 (10-23),
n = 25
16.0 (15-17),
n = 3
15.8 (12-19),
n = 18
12.0 (8-16),
n = 3
Disease duration, (range), mo 89.1 (17-300),
n = 109b
90.8 (24-300),
n = 49
81.5 (20-264),
n = 32
82.8 (36-120),
n = 4
107.0 (24-204),
n = 19
57.0 (17-151),
n = 5
Family historyc Probable: 17.0%
Possible: 30.0%
Probable: 22.4%
Possible: 22.4%
Probable: 19.2%
Possible: 30.8%
Possible: 75.0% Probable: 6.3%
Possible: 43.8%
Possible: 20.0%
a

Six patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) pathology were diagnosed clinically with motor neuron disease (MND) at some point after presentation. Mean age of onset = 51.3 years; mean education = 17.3 years; mean disease duration = 49.3 months.

b

Information regarding age at onset of dementia was not available in three patients.

c

Family history was coded according to the following criteria: definite = family history consistent with autosomal dominant pattern of inheritance (ie, at least three affected first-degree relatives in multiple generations) and/or identification of mutations in MAPT or valosin-containing protein genes; probable = two first-degree relatives with an FTLD diagnosis or related dementia; possible = one first-degree relative or two second-degree relatives with a diagnosis of FTLD or related dementia; none = no family history of FTLD or related condition. Information regarding family history was available in only 100 of the 114 patients.

DLDH = dementia lacking distinctive histopathology; AD = Alzheimer’s disease.